ArticleAmerican journal of translational research2021
Effect of resveratrol intervention on renal pathological injury and spermatogenesis in type 2 diabetic mice.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.
- Resveratrol delays the progression of diabetic nephropathy through multiple pathways: A dose-response meta-analysis based on animal models.Journal of diabetes · 2024Pooled it
- Gut-Testis Axis: Microbiota Prime Metabolome To Increase Sperm Quality in Young Type 2 Diabetes.Microbiology spectrum · 2022Article
- Antioxidant and Anti-inflammatory Properties of Resveratrol in Diabetic Nephropathy: A Systematic Review and Meta-analysis of Animal Studies.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes (T2D) is a clinically common cardiovascular disease that can lead to kidney damage and adversely affect male fertility and sperm quality. Resveratrol (Res) is a natural product that has a wide range of effects in animals and cell models.
objectiveThis research is designed to observe the effect of resveratrol (Res) intervention on renal pathologic injury and spermatogenesis in mice with type 2 diabetes (T2D).
methodsSixty healthy male SD mice without specific pathogens (SPF grade) were selected, and numbered by statistical software to randomize into control group (CG; n=20), model group (MG; n=20) and research group (RG; n=20). Mice in CG were given regular diet, while those in MG and RG were fed with high fat diet. Subsequently, RG was given Res intervention while MG received no treatment. Biochemical indexes [triglyceride (TG), total cholesterol (TC), fasting blood glucose (FBG), 24-hour urinary albumin excretion rate (24h-UAER)] of mice in the three groups before and after intervention were observed and recorded. The effect of Res on oxidative stress, kidney histopathological structure, spermatogenic function, sperm density and viability of mice, as well as spermatogenic cell cycle of testis were determined.
resultsRes reduced hyperlipidemia and hyperglycemia in T2D mice. By reducing malondialdehyde (MDA) and increasing superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), Res relieved oxidative stress and alleviated kidney tissue damage. In addition, Res improved the spermatogenic function of T2D mice by increasing the sperm density and survival rate and restoring the percentage of spermatogenic cells at all levels.
conclusionsRes intervention in T2D mice can reduce kidney tissue damage, lower blood glucose (BG), and improve spermatogenic function by increasing sperm density and restoring the percentage of spermatogenic cells at all levels.
Indexed as
Identifiers
34150052PMC8205790W3175270373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.